Replimune Group (NASDAQ:REPL) Trading Down 5.6% – Should You Sell?

Shares of Replimune Group, Inc. (NASDAQ:REPL) traded down 5.6% during trading on Friday . The stock traded as low as $10.99 and last traded at $10.95. 384,744 shares were traded during mid-day trading, a decline of 45% from the average session volume of 694,876 shares. The stock had previously closed at $11.60.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. HC Wainwright raised their price target on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. raised their price target on shares of Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Jefferies Financial Group raised their price target on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. Finally, BMO Capital Markets raised their price target on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Replimune Group currently has an average rating of “Buy” and an average price target of $19.43.

Replimune Group Stock Down 6.7 %

The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. The firm has a market cap of $833.30 million, a PE ratio of -3.52 and a beta of 1.30. The business’s 50-day simple moving average is $12.66 and its 200 day simple moving average is $12.15.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). As a group, equities research analysts expect that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Sterling Capital Management LLC boosted its holdings in shares of Replimune Group by 364.5% in the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock valued at $26,000 after buying an additional 1,655 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Replimune Group by 696.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock valued at $82,000 after buying an additional 5,922 shares in the last quarter. Aster Capital Management DIFC Ltd boosted its holdings in shares of Replimune Group by 8,798.9% in the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company’s stock valued at $100,000 after buying an additional 8,183 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Replimune Group in the 4th quarter valued at about $117,000. Finally, Quantinno Capital Management LP bought a new stake in shares of Replimune Group in the 4th quarter valued at about $127,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.